AffirmedRx’s Efforts to Address PBM Transparency and Drive Industry Change
November 25th 2024Greg Baker, CEO of AffirmedRx, shared with MHE editors how the company is addressing ongoing challenges in the pharmacy benefit management (PBM) industry, particularly corporate consolidation and transparency issues.
Read More
Tetris Used as Therapy to Reduce PTSD Symptoms in Pandemic Healthcare Workers
November 23rd 2024During the COVID-19 pandemic, healthcare workers faced several mental health challenges, experiencing repeated exposure to life-threatening situations that increased their risk of PTSD and other trauma-related conditions.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Read More
AIDS 2024, the 25th International AIDS Conference
October 6th 2024The International AIDS Society's meeting, AIDS 2024, the 25th International AIDS Conference, was held July 22-26 in Munich, Germany. Approximately 10,000 people attended the meeting, the largest in the world devoted to HIV and AIDS. Many of the sessions were live streamed and could be viewed remotely. Here is a sample of our coverage of the meeting.
Read More
A Conversation With Eric C. Hunter, MBA, CEO of CareOregon
September 8th 2024The president and CEO of CareOregon discussed the merger with SCAN Health that didn’t go through, Medicaid redetermination and the 2024 election with Managed Healthcare Executive (MHE) editors. Hunter is a member of MHE's editorial advisory board.
Read More
Group Purchasing Organizations of 'Big 3' PBMs Cloud Transparency, Says Critic | PBMI 2024
September 6th 2024Greg Baker, CEO of AffirmedRx, did not hold back in criticizing CVS Caremark, Optum Rx and Express Scripts and their group purchasing organizations today at the PBMI Annual National Conference.
Read More
Research Finds Virtual Care as Convenient but May Fail to Build Long-Term Patient Connections
August 29th 2024As Trilliant Health's Chief Research Officer, Sanjula Jain, Ph.D., and her team discovered that telehealth use is mostly driven by personal preferences — consumers who love the convenience, while others still prefer seeing a doctor in person because they think it's better quality. Listen in on the final interview of a three-part video series
Read More
Hospitals Should Consider Clinical Use, Payment Parity When Investing in Telehealth Post-Pandemic
August 28th 2024Sanjula Jain, Ph.D., chief research officer at Trilliant Health spoke with Managed Healthcare Executive in this part two interview on recent research that revealed where telehealth use stands after the pandemic. While its use is declining, Jain advised what areas are of best focus for investment.
Read More
Virtual Care's Role in Behavioral Health — Opportunities and Risks Highlighted Based on Recent Data
August 23rd 2024Virtual care offers a significant opportunity to bridge the gap between supply and demand in behavioral health services. However, there are risks associated with the lack of integration between virtual care and traditional healthcare systems, particularly in medication management.
Read More
Increased Risk of Rosacea Found in Former Smokers, But Connection is Hazy in Current Smokers
August 19th 2024People affected by rosacea can experience symptoms such as facial redness, flushing, and visible blood vessels. At times, they may also develop pimples or thickened skin, especially around the nose
Read More
LUNGevity's 'Breathe Deep TOGETHER' Campaign Brings Awareness to Lung Cancer Misconceptions
August 13th 2024One of the biggest misconceptions about lung cancer is that it only affects smokers, according to Amy Moore, vice president of Global Engagement and Research Partnerships at LUNGevity.
Read More
FDA Approves Citius Pharmaceuticals’ Lymphir for Cutaneous T-Cell Lymphoma
August 9th 2024In yesterday’s announcement, Citius shared Lymphir is the first and only CTCL therapy specifically targeting the interleukin-2 (IL-2) receptor found on malignant T-cells and regulatory T-cells (Tregs). The drug is also the first FDA-approved product for Citius.
Read More